FAQ

VePesid-Ifosfamide-Platinol Regimen

Known as: VP16-Ifosfamide-Platinol Regimen, Etoposide-Ifosfamide-Cisplatin Regimen, VIP 
A regimen consisting of etoposide, ifosfamide and cisplatin used for the treatment of advanced-stage germ cell gonadal cancers.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1976-2016
0519762016

Related topics

Related topics

5 relations
CisplatinEtoposideIfosfamideTesticular malignant germ cell tumor
(More)

Related mentions per year

Related mentions per year

1946-2018
19401960198020002020
VePesid-Ifosfamide-Platinol Regimen
Cisplatin
Etoposide
Ifosfamide
Testicular malignant germ cell tumor
cisplatin/etoposide/ifosfamide protocol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An…
BACKGROUND To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of… (More)
  • table 1
  • figure 1
  • table 3
  • table 2
  • table 5
Is this relevant?
2010
2010
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission… (More)
Is this relevant?
2008
2008
A randomized trial comparing compression, Perclose Proglide and Angio-Seal VIP for arterial closure following percutaneous coronary intervention: the CAP trial.
OBJECTIVE This prospective randomized trial compared the Angio-Seal VIP with Perclose Proglide and to manual compression with… (More)
Is this relevant?
2003
2003
Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an…
PURPOSE Patients with disseminated germ cell cancer and poor prognosis (International Germ Cell Cancer Collaborative Group… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
PURPOSE To compare first-line high-dose chemotherapy (HD-CT) with autologous blood stem-cell transplantation to standard-dose… (More)
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology…
PURPOSE To compare standard therapy with bleomycin, etoposide, and cisplatin (BEP) to experimental therapy with etoposide… (More)
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
Is this relevant?
1998
1998
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the…
PURPOSE To determine the effect of r-metHu granulocyte colony-stimulating factor (G-CSF) on the proportion of patients with… (More)
Is this relevant?
1998
1998
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group…
We investigated the efficacy and toxicity of induction chemotherapy with cisplatin and etoposide with either bleomycin or… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1993
1993
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
We report on the chemotherapy plus granulocyte colony-stimulating factor (G-CSF) induced mobilization of peripheral blood… (More)
Is this relevant?
1988
1988
Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide.
STUDY OBJECTIVE To determine the efficacy of the addition of ifosfamide to cisplatin plus etoposide (VIP), or vinblastine (VeIP… (More)
Is this relevant?